Fiera Capital Corp acquired a new position in shares of Eli Lilly And Co (NYSE:LLY) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 26,680 shares of the company’s stock, valued at approximately $3,506,000.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in LLY. Point72 Asset Management L.P. purchased a new position in Eli Lilly And Co during the 3rd quarter worth $101,403,000. BlackRock Inc. increased its holdings in Eli Lilly And Co by 1.5% during the 2nd quarter. BlackRock Inc. now owns 61,979,145 shares of the company’s stock worth $6,866,670,000 after purchasing an additional 898,845 shares during the period. Massachusetts Financial Services Co. MA increased its holdings in Eli Lilly And Co by 10.8% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 6,442,803 shares of the company’s stock worth $720,499,000 after purchasing an additional 628,267 shares during the period. PGGM Investments increased its holdings in Eli Lilly And Co by 1,490.6% during the 4th quarter. PGGM Investments now owns 545,015 shares of the company’s stock worth $71,631,000 after purchasing an additional 510,751 shares during the period. Finally, California Public Employees Retirement System increased its holdings in Eli Lilly And Co by 13.1% during the 3rd quarter. California Public Employees Retirement System now owns 4,096,921 shares of the company’s stock worth $458,159,000 after purchasing an additional 474,687 shares during the period. Institutional investors own 76.28% of the company’s stock.
In related news, SVP Myles O’neill sold 25,000 shares of the business’s stock in a transaction on Friday, December 6th. The stock was sold at an average price of $120.00, for a total transaction of $3,000,000.00. Following the transaction, the senior vice president now directly owns 40,424 shares in the company, valued at approximately $4,850,880. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, major shareholder Lilly Endowment Inc sold 10,598 shares of the business’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $114.00, for a total value of $1,208,172.00. Following the transaction, the insider now owns 116,210,304 shares in the company, valued at $13,247,974,656. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,609,483 shares of company stock worth $206,714,535. 0.11% of the stock is owned by company insiders.
Eli Lilly And Co (NYSE:LLY) last announced its earnings results on Thursday, January 30th. The company reported $1.73 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.52 by $0.21. Eli Lilly And Co had a return on equity of 188.01% and a net margin of 37.27%. The firm had revenue of $6.11 billion for the quarter, compared to the consensus estimate of $5.92 billion. During the same period in the previous year, the business earned $1.33 EPS. The firm’s revenue for the quarter was up 8.4% on a year-over-year basis. Research analysts predict that Eli Lilly And Co will post 6.76 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 14th will be paid a dividend of $0.74 per share. This represents a $2.96 annualized dividend and a yield of 2.10%. This is an increase from Eli Lilly And Co’s previous quarterly dividend of $0.65. The ex-dividend date of this dividend is Thursday, February 13th. Eli Lilly And Co’s payout ratio is 49.01%.
A number of research analysts have recently issued reports on LLY shares. Morgan Stanley upgraded Eli Lilly And Co from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $116.00 to $150.00 in a report on Wednesday, December 18th. They noted that the move was a valuation call. JPMorgan Chase & Co. lifted their price target on Eli Lilly And Co from $140.00 to $150.00 and gave the company an “overweight” rating in a report on Wednesday, December 18th. Mizuho started coverage on Eli Lilly And Co in a report on Wednesday, February 5th. They issued a “neutral” rating and a $148.00 price target on the stock. Cantor Fitzgerald reiterated a “buy” rating and issued a $156.00 price target on shares of Eli Lilly And Co in a report on Monday, February 3rd. Finally, Argus lifted their price target on Eli Lilly And Co from $145.00 to $165.00 and gave the company a “buy” rating in a report on Monday, December 30th. Six research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $137.36.
Eli Lilly And Co Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Recommended Story: What is the FTSE 100 index?
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.